drugset / Trial / NCT07096297
Luspatercept + Darbepoetin in MDS
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm open-label Phase II trial of luspatercept and darbepoetin alfa in non-mutated SF3B1 , lower-risk, RBC transfusion dependent MDS participants with an endogenous erythropoietin (EPO) level \< 500 IU/L.
Timeline
- Start
- 2025-12-16
- Primary completion
- 2030-08
- Completion
- 2030-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 300 ug | Subcutaneous |
| Subject | Luspatercept | Protein / enzyme biologic | 1 mg/kg | Subcutaneous |